Inhibition of amyloid fibril formation and cytotoxicity by hydroxyindole derivatives

Biochemistry

Volumn 45, Issue 15, 2006, Pages 4727-4735

  Cohen, Tomer ^a   Frydman Marom, Anat ^a   Rechter, Meirav ^a   Gazit, Ehud ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

AROMATIC COMPOUNDS; DERIVATIVES; DISEASES; ELECTRON MICROSCOPY; POLYPEPTIDES; SELF ASSEMBLY;

AMYLOID INHIBITION; CYTOTOXIC ACTIVITY; FIBRILLIZATION INHIBITORS;

TOXICITY;

3 INDOLEMETHANOL; 4 HYDROXYINDOLE; AMYLOID; AMYLOID BETA PROTEIN; INDOLE DERIVATIVE; INDOXYL; TRYPTOPHAN; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL CELL; ARTICLE; ATOMIC FORCE MICROSCOPY; BINDING AFFINITY; CHEMICAL STRUCTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DEGENERATIVE DISEASE; FLUORESCENCE SPECTROSCOPY; INCUBATION TIME; MOLECULAR RECOGNITION; MOLECULAR WEIGHT; NONHUMAN; PHEOCHROMOCYTOMA CELL; PRIORITY JOURNAL; PROTEIN AGGREGATION; RAT; TRANSMISSION ELECTRON MICROSCOPY;

AMYLOID; ANIMALS; ANTIOXIDANTS; DOSE-RESPONSE RELATIONSHIP, DRUG; INDOLES; KINETICS; MICROSCOPY, ELECTRON, TRANSMISSION; PC12 CELLS; PEPTIDE FRAGMENTS; RATS; SPECTROMETRY, FLUORESCENCE; STRUCTURE-ACTIVITY RELATIONSHIP; TIME FACTORS;

ANIMALIA;

EID: 33645929400     PISSN: 00062960     EISSN: None     Source Type: Journal    
DOI: 10.1021/bi051525c     Document Type: Article

References (62)

1. Haass, C., and De Strooper, B. (1999) The presenilins in Alzheimer's disease proteolysis holds the key, Science 286, 916-919.
2. Selkoe, D. J. (2002) Alzheimer's disease is a synaptic failure, Science 298, 789-791.
3. Buee, L., Bussiere, T., Buee-Scherrer, V., Delacourte, A., and Hof, P. R. (2000) Tau protein isoforms, phosphorylation and role in neurodegenerative disorders, Brain Res. Rev. 33, 95-130.
4. Caughey, B., and Lansbury, P. T., Jr. (2003) Protofibrils, pores, fibrils, and neurodegeneration: Separating the responsible protein aggregates from the innocent bystanders, Annu. Rev. Neurosci. 26, 267-298.
5. Pike, C. J., Burdick, D., Walencewicz, A. J., Glabe, C. G., and Cotman, C. W. (1993) Neurodegeneration induced by β-amyloid peptides in vitro: The role of peptide assembly state, J. Neurosci. 13, 1676-1687.
6. Lorenzo, A., and Yankner, B. A. (1994) β-Amyloid neurotoxicity requires fibril formation and is inhibited by Congo red, Proc. Natl. Acad. Sci. U.S.A. 91, 12243-12247.
7. Grace, E. A., Rabiner, C. A., and Busciglio, J. (2002) Characterization of neuronal dystrophy induced by fibrillar amyloid β: Implications for Alzheimer's disease, Neuroscience 114, 265-273.
8. Lambert, M. P., Barlow, A. K., Chromy, B. A., Edwards, C., Freed, R., Liosatos, M., Morgan, T. E., Rozovsky, I., Trommer, B., Viola, K. L., Wals, P., Zhang, C., Finch, C. E., Krafft, G. A., and Klein, W. L. (1998) Diffusible, nonfibrillar ligands derived from Aβ1-42 are potent central nervous system neurotoxins, Proc. Natl. Acad. Sci. U.S.A. 95, 6448-6453.
9. Wang, H. W., Pasternak, J. F., Kuo, H., Ristic, H., Lambert, M. P., Chromy, B., Viola, K. L., Klein, W. L., Stine, W. B., Krafft, G. A., and Trommer, B. L. (2002) Soluble oligomers of β amyloid (1-42) inhibit long-term potentiation but not long-term depression in rat dentate gyrus, Brain Res. 924, 133-140.
10. Walsh, D. M., Klyubin, I., Fadeeva, J. V., Rowan, M. J., and Selkoe, D. J. (2002) Amyloid-β oligomers: Their production, toxicity and therapeutic inhibition, Biochem. Soc. Trans. 30, 552-557.
11. Kim, H. J., Chae, S. C., Lee, D. K., Chromy, B., Lee, S. C., Park, Y. C., Klein, W. L., Krafft, G. A., and Hong, S. T. (2003) Selective neuronal degeneration induced by soluble oligomeric amyloid beta protein, FASEB J. 17, 118-120.
12. Kayed, R., Head, E., Thompson, J. L., McIntire, T. M., Milton, S. C., Cotman, C. W., and Glabe, C. G. (2003) Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis, Science 300, 486-489.
13. Lashuel, H. A., Hartley, D., Petre, B. M., Walz, T., and Lansbury, P. T., Jr. (2002) Neurodegenerative disease: Amyloid pores from pathogenic mutations, Nature 418, 291.
14. Porat, Y., Kolusheva, S., Jelinek, R., and Gazit, E. (2003) The human islet amyloid polypeptide forms transient membrane-active protofilaments, Biochemistry 42, 10971-10977.
15. Cleary, J. P., Walsh, D. M., Hofmeister, J. J., Shankar, G. M., Kuskowski, M. A., Selkoe, D. J., and Ashe, K. H. (2004) Natural oligomers of the amyloid protein specifically disrupt cognitive function, Nat. Neurosci. 8, 79-84.
16. Bitan, G., Fradinger, E. A., Spring, S. M., and Teplow, D. B. (2005) Neurotoxic protein oligomers: What you see is not always what you get, Amyloid 12, 88-95.
17. Klein, W. L., Stine, W. B., Jr., and Teplow, D. B. (2004) Small assemblies of unmodified amyloid β-protein are the proximate neurotoxin in Alzheimer's disease, Neurobiol. Aging 25, 569-580.
18. El-Agnaf, O. M., Nagala, S., Patel, B. P., and Austen, B. M. (2001) Non-fibrillar oligomeric species of the amyloid ABri peptide, implicated in familial British dementia, are more potent at inducing apoptotic cell death than protofibrils or mature fibrils, J. Mol. Biol. 310, 157-168.
19. El-Agnaf, O. M., Mahil, D. S., Patel, B. P., and Austen, B. M. (2000) Oligomerization and toxicity of β-amyloid-42 implicated in Alzheimer's disease, Biochem. Biophys. Res. Commun. 273, 1003-1007.
20. Tjernberg, L. O., Naslund, J., Lindqvist, F., Iohansson, J., Karlstrom, A. R., Thyberg, J., Terenius, L., and Nordstedt, C. (1996) Arrest of β-amyloid fibril formation by a pentapeptide ligand, J. Biol. Chem. 271, 8545-8548.
21. Balbach, J. J., Ishii, Y., Antzutkin, O. N., Leapman, R. D., Rizzo, N. W., Dyda, F., Reed, J., and Tycko, R. (2000) Amyloid fibril formation by Aβ 16-22, a seven-residue fragment of the Alzheimer's β-amyloid peptide, and structural characterization by solid-state NMR, Biochemistry 39, 13748-13759.
22. Findeis, M. A., Musso, G. M., Arico-Muendel, C. C., Benjamin, H. W.; Hundal, A. M., Lee, J. J., Chin, J., Kelley, M., Wakefield, J., Hayward, N. J., and Molineaux, S. M. (1999) Modified-peptide inhibitors of amyloid-β- peptide polymerization, Biochemistry 38, 6791-6800.
23. Soto, C., Sigurdsson, E. M., Morelli, L., Kumar, R. A., Castano, E. M., and Frangione, B. (1998) β-Sheet breaker peptides inhibit fibrillogenesis in a rat brain model of amyloidosis: Implications for Alzheimer's therapy, Nat. Med. 4, 822-826.
24. Zhang, G., Leibowitz, M. J., Sinko, P. J., and Stein, S. (2003) Multiple-peptide conjugates for binding β-amyloid plaques of Alzheimer's disease, Bioconjugate Chem. 14, 86-92.
25. Gazit, E. (2002) A possible role for π-stacking in the self-assembly of amyloid fibrils, FASEB J. 16, 77-83.
26. Aggeli, A., Bell, M., Boden, N., Keen, J. N., Knowles, P. F., McLeish, T. C., Pitkeathly, M., and Radford, S. E. (1997) Responsive gels formed by the spontaneous self-assembly of peptides into polymeric β-sheet tapes, Nature 386, 259-262.
27. Claessens, C. G., and Stoddart, J. F. (1997) Aromatic interactions in self-assembly, J. Phys. Org. Chem. 10, 254-272.
28. Burley, S. K., and Petsko, G. A. (1985) Aromatic-aromatic interaction: A mechanism of protein structure stabilization, Science 229, 23-28.
29. Hunter, C. A., Lawson, K. R., Perkins, J., and Urch, C. J. (2001) Aromatic interactions, J. Chem. Soc., Perkin Trans. 2, 651-669.
30. Tenidis, K., Waldner, M., Bernhagen, J., Fischle, W., Bergmann, M., Weber, M., Merkle, M. L., Voelter, W., Brunner, H., and Kapurniotu, A. (2000) Identification of a penta- and hexapeptide of islet amyloid polypeptide (IAPP) with amyloidogenic and cytotoxic properties, J. Mol. Biol. 295, 1055-1071.
31. Azriel, R., and Gazit, E. (2001) Analysis of the minimal amyloid-forming fragment of the islet amyloid polypeptide. An experimental support for the key role of the phenylalanine residue in amyloid formation, J. Biol. Chem. 276, 34156-34161.
32. Reches, M., Porat, Y., and Gazit, E. (2002) Amyloid fibril formation by pentapeptide and tetrapeptide fragments of human calcitonin, J. Biol. Chem. 277, 35475-35480.
33. Jones, S., Manning, J., Kad, N. M., and Radford, S. E. (2003) Amyloid-forming peptides from 2-microglobulin: Insights into the mechanism of fibril formation in vitro, J. Mol. Biol. 325, 249-257.
34. Mazor, Y., Gilead, S., Benhar, I., and Gazit, E. (2002) Identification and Characterization of a Novel Molecular-Recognition and Self-Assembly Domain in the Islet Amyloid Polypeptide, J. Mol. Biol. 322, 1013-1024.
35. Reches, M., and Gazit, E. (2004) Amyloidogenic Hexapeptide Fragment of Medin: Implications for the Stacking Model of Fibrillization, Amyloid 11, 81-89.
36. 13C solid-state NMR spectroscopy, Magn. Reson. Chem. 42, 247-257.
37. Makin, O. S., Atkins, E., Sikorski, P., Johansson, J., and Serpell, L. C. (2005) Molecular basis for amyloid fibril formation and stability, Proc. Natl. Acad. Sci. U.S.A. 102, 315-320.
38. Tartaglia, G. G., Cavalli, A., Pellarin, R., and Caflisch, A. (2004) The role of aromaticity, exposed surface, and dipole moment in determining protein aggregation rates, Protein Sci. 13, 1939-1941.
39. Zanuy, D., and Nussinov, R. (2003) The sequence dependence of fiber organization. A comparative molecular dynamics study of the islet amyloid polypeptide segments 22-27 and 22-29, J. Mol. Biol. 329, 565-584.
40. Zanuy, D., Porat, Y., Gazit, E., and Nussinov, R. (2004) Peptide sequence and amyloid formation: Molecular simulations and experimental study of a human islet amyloid polypeptide fragment and its analogues, Structure 12, 439-455.
41. Colombo, G., Daidone, I., Gazit, E., Amadei, A., and Di Nola, A. (2005) Molecular dynamics simulation of the aggregation of the core-recognition motif of the islet amyloid polypeptide in explicit water, Proteins 59, 519-527.
42. Haspel, N., Zanuy, D., Ma, B., Wolfson, H., and Nussinov, R. (2005) A comparative study of amyloid fibril formation by residues 15-19 of the human calcitonin hormone: A single β-sheet model with a small hydrophobic core, J. Mol. Biol. 345, 1213-1227.
43. Wu, C., Lei, H., and Duan, Y. (2005) The role of Phe in the formation of well-ordered oligomers of amyloidogenic hexapeptide (NFGAIL) observed in molecular dynamics simulations with explicit solvent, Biophys. J. 88, 2897-2906.
44. Pawar, A. P., DuBay, K. F., Zurdo, J., Chiti, F., Vendruscolo, M.; and Dobson, C. M. (2005) Prediction of "aggregation-prone" and "aggregation susceptible" regions in proteins associated with neurodegenerative diseases, J. Mol. Biol. 350, 379-392.
45. Porat, Y., Stepensky, A., Ding, F. X., Naider, F., and Gazit, E. (2003) Completely different amyloidogenic potential of nearly identical peptide fragments, Biopolymers 69, 161-164.
46. Porat, Y., Mazor, Y., Efrat, S., and Gazit, E. (2004) Inhibition of islet amyloid polypeptide fibril formation: A potential role for heteroaromatic interactions, Biochemistry 43, 14454-14462.
47. Chyan, Y. J., Poeggeler, B., Omar, R. A., Chain, D. G., Frangione, B., Ghiso, J., and Pappolla, M. A. (1999) Potent neuroprotective properties against the Alzheimer β-amyloid by an endogenous melatonin-related indole structure, indole-3-propionic acid, J. Biol. Chem. 274, 21937-21942.
48. Bendheim, P. E., Poeggeler, B., Neria, E., Ziv, V., Pappolla, M. A., and Chain, D. G. (2002) Development of indole-3-propionic acid (OXIGON) for Alzheimer's disease, J. Mol. Neurosci. 19, 213-217.
49. Hansen, M. B., Nielsen, S. E., and Berg, K. (1989) Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill, J. Immunol. Methods 119, 203-210.
50. Jarrett, J. T., Berger, E. P., and Lansbury, P. T., Jr. (1993) The carboxy terminus of the β amyloid protein is critical for the seeding of amyloid formation: Implications for the pathogenesis of Alzheimer's disease, Biochemistry 32, 4693-4697.
51. Nanda, V., and Brand, L. (2000) Aromatic interactions in homeodomains contribute to the low quantum yield of a conserved, buried tryptophan, Proteins 40, 112-125.
52. Burley, S. K., and Petsko, G. A. (1985) Aromatic-aromatic interaction: A mechanism of protein structure stabilization, Science 229, 23-28.
53. Qin, X. R., Abe, H., and Nakanishi, H. (2002) NMR and CD studies on the interaction of Alzheimer β-amyloid peptide (12-28) with β-cyclodextrin, Biochem. Biophys. Res. Commun. 297, 1011-1015.
54. Walsh, D. M., Klyubin, I., Fadeeva, J. V., Cullen, W. K., Anwyl, R., Wolfe, M. S., Rowan, M. J., and Selkoe, D. J. (2002) Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo, Nature 416, 535-539.
55. Klein, W. L., Krafft, G. A., and Finch, C. E. (2001) Targeting small Aβ oligomers: The solution to an Alzheimer's disease conundrum? Trends Neurosci. 24, 219-224.
56. Cohen, F. E., and Kelly, J. W. (2003) Therapeutic approaches to protein-misfolding diseases, Nature 426, 905-909.
57. Gazit, E. (2004) The role of prefibrillar assemblies in the pathogenesis of amyloid diseases, Drugs Future 29, 613-619.
58. Jarrett, J. T., and Lansbury, P. T., Jr. (1993) Seeding one-dimensional crystallization of amyloid: A pathogenic mechanism in Alzheimer's disease and scrapie? Cell 73, 1055-1058.
59. Naiki, H., Gejyo, F., and Nakakuki, K. (1997) Concentration-dependent inhibitory effects of apolipoprotein E on Alzheimer's β-amyloid fibril formation in vitro, Biochemistry 36, 6243-6250.
60. De Felice, F. G., Vieira, M. N., Saraiva, L. M., Figueroa-Villar, J. D., Garcia-Abre, J., Liu, R., Chang, L., Klein, W. L., and Ferreira, S. T. (2004) Targeting the neurotoxic species in Alzheimer's disease: Inhibitors of Aβ oligomerization, FASEB J. 18, 1366-1372.
61. Ono, K., Yoshiike, Y., Takashima, A., Hasegawa, K., Naiki, H., and Yamada, M. (2003) Potent anti-amyloidogenic and fibril-destabilizing effects of polyphenols in vitro: Implications for the prevention and therapeutics of Alzheimer's disease, J. Neurochem. 87, 172-181.
62. Kocisko, D. A., Baron, G. S., Rubenstein, R., Chen, J., Kuizon, S., and Caughey, B. (2003) New inhibitors of scrapie-associated prion protein formation in a library of 2000 drugs and natural products, J. Virol. 77, 10288-10294.